Ivonescimab HARMONi-2 Overall Survival Win vs Pembrolizumab
Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Sep 13, 2026
The positive OS data strengthen ivonescimab's competitive position against pembrolizumab, Merck & Co.'s blockbuster Keytruda, potentially pressuring Merck's oncology franchise in first-line PD-L1-positive NSCLC while boosting Akeso's pipeline value and licensing prospects. Broader market impact is limited to the oncology and biotech sectors, with Akeso shares likely to react positively and Merck shares facing modest sentiment headwinds.
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF bispecific antibody, demonstrated statistically significant and clinically meaningful improvement over pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1 (TPS >=1%). At the 2026 World Conference on Lung Cancer organized by the International Association for the Study of Lung Cancer, full OS data were published on the conference website on September 13, 2026, with a formal oral presentation scheduled for September 15 by Principal Investigator Caicun Zhou, IASLC President and Director of Oncology at Shanghai East Hospital. As of the August 20, 2026 data cutoff, median follow-up was 36 months with 234 OS events. In the intention-to-treat population, median OS was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab (HR=0.73; 95% CI 0.57-0.95; P=0.009), a 27% reduction in risk of death. Benefit was consistent across subgroups, with a 42% reduction in risk of death in the PD-L1 TPS >=50% population (HR=0.58). No new safety signals emerged, and no apparent increase in bleeding risk was observed in high-risk squamous patients, a population traditionally contraindicated for anti-VEGF therapies. In May 2024 the trial had already met its primary progression-free survival endpoint (11.14 vs 5.82 months; HR=0.51), and the indication received regulatory approval in China in 2025. HARMONi-2 is the first randomized, double-blind, controlled Phase III study to show statistically significant positive OS and PFS results versus pembrolizumab. Akeso CEO Xia Yu (actor) highlighted the growing body of evidence supporting ivonescimab across solid tumors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard